Understand the source comparison
Best Peptides for Female Orgasm Difficulty: Research Compound Comparison
Bremelanotide (PT-141) MC3R/MC4R agonist. Increases hypothalamic dopamine and arousal signaling Subcutaneous injection (1.75mg) FDA-approved for HSDD; Phase 3 RCT data 40% experience nausea in first 2 doses; requires 45-min pre-activity timing Oxytocin Parasym
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Bremelanotide (PT-141)
- MC3R/MC4R agonist. Increases hypothalamic dopamine and arousal signaling
- Subcutaneous injection (1.75mg)
- FDA-approved for HSDD; Phase 3 RCT data
- 40% experience nausea in first 2 doses; requires 45-min pre-activity timing
- Oxytocin
- Parasympathetic activation. Enhances genital blood flow and reduces cortisol-mediated arousal inhibition
- Intranasal (24–40 IU) or subcutaneous
- Pilot trials only; inconsistent effect sizes
- Poor intranasal bioavailability (<0.05% CNS penetration); <10 min half-life limits dosing precision
- Kisspeptin-54
- GnRH pulse generator. Restores HPG axis signaling and downstream sex hormone production
- Intravenous (1–4 nmol/kg)
- Early-phase clinical trials; fMRI-confirmed limbic activation
- IV-only route limits accessibility; not approved for sexual dysfunction; investigational use only